MiMedx Shares to Commence Trading on Nasdaq on Wednesday, November 4, 2020
MiMedx Group, Inc. (OTC PINK: MDXG) announced that its common stock will begin trading on The Nasdaq Stock Market from November 4, 2020.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
MiMedx Group, Inc. (OTC PINK: MDXG) announced that its common stock will begin trading on The Nasdaq Stock Market from November 4, 2020. This move marks a significant milestone for the company, which specializes in advanced wound care and therapeutic biologics. MiMedx is recognized for its development and distribution of human placental tissue allografts using its proprietary PURION® process. The company has successfully supplied over two million allografts to the healthcare sector.
Positive
- Commencement of trading on Nasdaq under the ticker symbol 'MDXG' enhances visibility and credibility.
- Established reputation as an industry leader in advanced wound care and therapeutic biologics.
Negative
- None.
Details
News Market Reaction – MDXG
The recorded move for MDXG in the trading session of this news was +10.21%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MARIETTA, Ga., Nov. 03, 2020 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (OTC PINK: MDXG) (“MiMedx” or the “Company”), an industry leader in advanced wound care and a therapeutic biologics company, today confirmed that the Company’s common stock will commence trading on The Nasdaq Stock Market at the opening of trading on Wednesday, November 4, 2020, under the ticker symbol “MDXG”.
About MiMedx
MiMedx® is an industry leader in advanced wound care and a therapeutic biologics company developing and distributing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare. The Company processes the human placental tissue utilizing its proprietary PURION® process methodology, among other processes, to produce allografts by employing aseptic processing techniques in addition to terminal sterilization. MiMedx has supplied over two million allografts, through both direct and consignment shipments. For additional information, please visit www.mimedx.com.
Contact
Hilary Dixon
Investor Relations & Corporate Communications
770.651.9066
investorrelations@mimedx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.